Oncology Dictionary
Instant, high-precision reference for clinical short forms, genomic biomarkers, molecular subtypes, diagnostic tests, and surgical regimens in breast cancer care.
BCPBD
Breast Cancer Portal of Bangladesh
The national biomedical research portal and clinical data repository aggregating epidemiological, clinical, and genomic data from Bangladeshi breast cancer patients to support translational oncology and precision care.
Developed by the Department of Genetic Engineering & Biotechnology at the University of Dhaka, BCPBD provides native datasets, statistical calculators, and TCGA-integrated research tools tailored to the Bangladeshi and South Asian population.
TNBC
Triple-Negative Breast Cancer
A breast cancer subtype whose tumor cells lack estrogen receptors (ER-), progesterone receptors (PR-), and human epidermal growth factor receptor 2 (HER2-).
Comprises approximately 15-20% of cases worldwide but exhibits higher prevalence in South Asian populations. Does not respond to endocrine therapy or HER2-targeted agents; managed primarily with chemotherapy, PARP inhibitors, and immunotherapy.
ER
Estrogen Receptor
A nuclear hormone receptor protein that binds estrogen hormones. When breast cancer cells test positive for ER (ER+), estrogen stimulates their growth and survival.
Expressed in approximately 70-80% of breast cancer diagnoses. Serves as the primary biomarker for prescribing endocrine therapies such as Tamoxifen and Aromatase Inhibitors.
PR
Progesterone Receptor
An intracellular steroid receptor regulated by estrogen and activated by progesterone. Tested alongside ER during routine immunohistochemical profiling.
PR expression reflects a functionally intact estrogen signaling pathway. High PR positivity combined with ER positivity is indicative of the favorable Luminal A subtype.
HER2 / neu
Human Epidermal Growth Factor Receptor 2 (ERBB2)
A receptor tyrosine kinase encoded by the ERBB2 oncogene on chromosome 17q. Promotes cellular proliferation and inhibits apoptosis when overexpressed or amplified.
Amplified or overexpressed in 15-20% of invasive breast carcinomas. Targeted directly with monoclonal antibodies (Trastuzumab, Pertuzumab) and antibody-drug conjugates (T-DXd).
TNM Staging
Tumor, Node, Metastasis Staging System
The globally standard oncology staging classification developed by the AJCC and UICC, evaluating primary Tumor size/extent (T), regional lymph Node metastasis (N), and distant Metastasis (M).
Forms the bedrock of clinical decision-making, stratifying cancers from Stage 0 (in situ) through Stage IV (distant metastasis) to determine curative versus palliative treatment intent.
IDC
Invasive Ductal Carcinoma (No Special Type - NST)
Malignant breast carcinoma that originated inside mammary milk ducts and has breached the basement membrane to infiltrate neighboring breast stroma and adipose tissue.
The single most common histological type of breast cancer, representing 75-80% of all invasive breast cancer diagnoses globally and in the BCPBD registry.
ILC
Invasive Lobular Carcinoma
Invasive breast cancer arising in the milk-producing lobules, characterized histologically by single-file linear infiltration of discohesive cells due to loss of the cell adhesion protein E-cadherin (CDH1).
Accounts for 10-15% of breast cancers. Often difficult to palpate and detect on mammography; frequently bilateral and multicentric.
DCIS
Ductal Carcinoma In Situ
A non-invasive proliferation of malignant-appearing epithelial cells inside the mammary milk ducts without penetration across the epithelial basement membrane.
Classified as Stage 0 cancer. Frequently diagnosed on screening mammograms via microcalcifications. High cure rate following lumpectomy and radiation.
LCIS
Lobular Carcinoma In Situ
An atypical non-invasive proliferation of discohesive cells expanding breast lobules without breaching the lobular basement membrane.
Historically regarded as a pre-cancer, now recognized primarily as a high-risk indicator and marker for subsequent bilateral invasive breast cancer development.
IBC
Inflammatory Breast Cancer
A rare, fast-progressing, locally advanced breast cancer where malignant cells obstruct dermal lymphatic channels, causing generalized redness, swelling, warmth, and an orange-peel (peau d'orange) skin texture.
Staged at presentation as Stage IIIB or Stage IV. Requires immediate neoadjuvant chemotherapy before modified radical mastectomy and post-mastectomy radiation.
MBC
Metastatic Breast Cancer (Stage IV)
Advanced breast cancer that has disseminated through the vascular or lymphatic systems to distant anatomical organs, predominantly bones, lungs, liver, brain, or distant nodes.
Managed with ongoing systemic therapies (targeted agents, endocrine therapy, chemotherapy, CDK4/6 inhibitors) focused on disease stabilization and extending quality of life.
FNAC
Fine Needle Aspiration Cytology
A rapid diagnostic procedure using a fine-gauge needle (21-25 gauge) and syringe to extract individual cells and fluid from a palpable breast lump for microscopic cytology.
Widely used across district and tertiary hospitals in Bangladesh for rapid primary triaging, though core needle biopsy is necessary to confirm invasion and perform receptor IHC.
CNB
Core Needle Biopsy
A tissue-sampling procedure utilizing a wide-bore spring-loaded needle (14-16 gauge) under local anesthesia to harvest intact cylinders (cores) of solid breast tissue.
The worldwide gold standard for definitive breast cancer diagnosis. Differentiates in situ from invasive lesions and supplies adequate tissue for ER, PR, HER2, and Ki-67 tests.
BI-RADS
Breast Imaging Reporting and Data System
The standardized scoring system developed by the American College of Radiology (ACR) to categorize mammography, breast ultrasound, and MRI findings from 0 (incomplete) to 6 (proven malignancy).
BI-RADS 1 = Negative; BI-RADS 2 = Benign; BI-RADS 3 = Probably benign (short-interval follow-up); BI-RADS 4 = Suspicious (biopsy recommended); BI-RADS 5 = Highly suggestive of malignancy (biopsy required).
BCS
Breast Conserving Surgery (Lumpectomy)
Surgical excision of the primary malignant breast tumor along with a margin of healthy normal surrounding tissue, preserving the remaining breast contour and structure.
Standard surgical option for early-stage operable breast cancer when combined with postoperative radiotherapy, demonstrating equivalent overall survival to total mastectomy.
MRM
Modified Radical Mastectomy
Surgical removal of the entire breast parenchyma, nipple-areola complex, and axillary lymph nodes (Levels I & II) while preserving the underlying pectoralis major muscle.
The most commonly performed mastectomy procedure in Bangladesh for multicentric disease, large tumors, or where postoperative radiation therapy is unavailable or contraindicated.
SLNB
Sentinel Lymph Node Biopsy
Identification, surgical removal, and histological examination of the first lymph node(s) receiving drainage from the primary breast tumor using radioactive tracer or isosulfan/methylene blue dye.
Spares patients without nodal metastasis from comprehensive axillary clearance, dramatically reducing the risk of chronic upper-limb lymphedema.
ALND
Axillary Lymph Node Dissection
Surgical clearance of Levels I and II axillary fat pads containing between 10 to 20 or more lymph nodes for staging and local regional disease control.
Indicated when pre-operative biopsy or sentinel node evaluation demonstrates extensive nodal metastasis. Carries a higher incidence of lymphedema and numbness.
NAC
Neoadjuvant Chemotherapy
Systemic chemotherapy given before primary surgical intervention to shrink large primary tumors and eradicate occult micrometastases.
Downstages tumors to permit breast-conserving surgery instead of mastectomy and provides real-time in vivo assessment of tumor drug sensitivity.
pCR
Pathological Complete Response
The total absence of viable invasive cancer cells in surgical breast tissue and regional axillary nodes upon histological examination after neoadjuvant systemic therapy (ypT0/is ypN0).
A premier surrogate endpoint strongly predicting favorable event-free and overall survival, especially in HER2-positive and triple-negative breast cancer subtypes.
IHC
Immunohistochemistry
A laboratory diagnostic staining technique using antigen-specific antibodies linked to enzymes or fluorophores to detect receptor protein expression in formalin-fixed paraffin-embedded tissue sections.
Standard technique for establishing ER, PR, HER2 (0 to 3+), and Ki-67 proliferation status to classify tumors into intrinsic molecular subtypes.
FISH
Fluorescence In Situ Hybridization
A molecular cytogenetic technique utilizing fluorescently labeled DNA probes that hybridize specifically to the ERBB2 gene locus on chromosome 17 to determine copy number amplification.
The definitive confirmatory test for equivocal (IHC 2+) HER2 breast cancer cases to determine whether the patient is a candidate for Trastuzumab/HER2 targeted agents.
SERM
Selective Estrogen Receptor Modulator
Synthetic pharmacological compounds that act as estrogen receptor antagonists in breast tissue while exerting estrogenic agonist effects in other organs like bone and endometrium.
Tamoxifen is the benchmark SERM, prescribed for 5 to 10 years to reduce recurrence and mortality in both premenopausal and postmenopausal ER+ breast cancer.
AI
Aromatase Inhibitor
A class of oral endocrine medications (Letrozole, Anastrozole, Exemestane) that inhibit the aromatase cytochrome P450 enzyme, halting peripheral androgen conversion into estrogens.
Standard first-line adjuvant hormonal treatment for postmenopausal women with hormone receptor-positive breast cancer, superior to Tamoxifen in this population.
CDK4/6 Inhibitor
Cyclin-Dependent Kinase 4 and 6 Inhibitors
A class of targeted therapeutic kinase inhibitors (Palbociclib, Ribociclib, Abemaciclib) that block enzymes regulating cell cycle progression from G1 to S phase.
Combined with endocrine therapy to substantially prolong progression-free and overall survival in hormone receptor-positive, HER2-negative metastatic and high-risk early breast cancer.
ADC
Antibody-Drug Conjugate
A biopharmaceutical class consisting of a monoclonal antibody linked via a chemical linker to a cytotoxic drug payload (e.g., T-DXd / Trastuzumab Deruxtecan, T-DM1, Sacituzumab Govitecan).
Delivers potent chemotherapy selectively into cancer cells expressing targeted surface receptors (HER2, Trop-2), revolutionizing outcomes in HER2-positive, HER2-low, and TNBC patients.
NGS
Next-Generation Sequencing
High-throughput massively parallel sequencing technologies allowing rapid, simultaneous sequencing of millions to billions of DNA/RNA fragments across targeted gene panels or whole exomes.
Enables comprehensive genomic profiling for actionable somatic mutations (PIK3CA, ESR1, BRCA1/2), copy number changes, and research discoveries featured in the TCGA/BCPBD portals.
TMB
Tumor Mutational Burden
The total number of non-synonymous somatic mutations detected per megabase (mut/Mb) of sequenced tumor genomic coding region.
High TMB (≥10 mutations/Mb) generates tumor neoantigens that trigger host immune responses, serving as an FDA-approved predictive biomarker for immune checkpoint inhibitors (e.g., Pembrolizumab).
CNA / CNV
Copy Number Alteration / Variation
Somatic chromosomal changes resulting in an abnormal number of copies of specific DNA segments, categorized as high-level amplifications, gains, shallow deletions, or deep homozygous deletions.
Drives oncogene overexpression (e.g., ERBB2, CCND1, MYC amplification) and tumor suppressor loss (e.g., PTEN, RB1 deletions) tracked across the BCPBD and TCGA portals.
SNV
Single Nucleotide Variant
A variation or mutation involving a change in a single nucleotide base (A, C, G, or T) in a genomic DNA sequence.
The most prevalent form of somatic cancer mutations, responsible for activating hotspots in oncogenes like PIK3CA and inactivating mutations in TP53.
Indel
Insertion-Deletion Mutation
A genomic mutation characterized by the insertion or deletion of small segments of nucleotide bases (1 to <50 bp) in the genomic DNA sequence.
Frequently causes frameshift alterations in tumor suppressor genes, leading to premature truncation of proteins like BRCA1 and BRCA2.
FPKM / TPM
Fragments Per Kilobase Million / Transcripts Per Kilobase Million
Normalized expression metrics in RNA-sequencing that standardize raw read counts by adjusting for both gene transcript length and total sequenced library depth.
Employed throughout the TCGA and BCPBD gene expression analysis modules to accurately compare mRNA expression levels between tumor and normal tissues.
OS
Overall Survival
The duration of time from the date of cancer diagnosis or the initiation of treatment to the date of death from any cause.
Universally acknowledged as the premier gold-standard clinical outcome metric in cancer epidemiology, clinical trials, and Kaplan-Meier analyses.
DFS
Disease-Free Survival
The length of time following curative-intent primary treatment (e.g. surgery + adjuvant therapy) that a patient survives without any sign of cancer recurrence (local or distant).
Key primary outcome measure evaluating the curative potential of adjuvant surgical, systemic, and radiotherapeutic treatments.
PFS
Progression-Free Survival
The duration of time during and following cancer therapy that a patient lives with the disease without the tumor progressing, enlarging, or spreading further.
Critical efficacy benchmark in clinical trials of advanced and metastatic breast cancer assessing the durability of targeted therapies and chemotherapy.
HR
Hazard Ratio (or Hormone Receptor)
In survival statistics (Cox proportional hazards models), the ratio of the hazard (risk) rate in an exposed/treated cohort relative to an unexposed/control cohort. In clinical biology, also commonly denotes Hormone Receptor (ER/PR).
An HR < 1.0 demonstrates that a therapeutic intervention reduces risk of relapse or death; an HR > 1.0 indicates elevated risk. Core parameter in BCPBD survival models.
OR
Odds Ratio
A statistical ratio quantifying the strength of association between an exposure (e.g. high BMI, parity, diabetes) and an outcome (breast cancer occurrence) in case-control epidemiological studies.
An OR = 1.0 means no association; OR > 1.0 indicates exposure is associated with higher disease odds. Central to the BCPBD 2x2 contingency table calculator.
CI (95% CI)
95% Confidence Interval
A computed statistical range that has a 95% probability of containing the true population parameter (e.g. true Odds Ratio or Hazard Ratio).
Indicates precision of an estimate. If the 95% CI of an Odds Ratio or Hazard Ratio does not cross 1.0, the finding is regarded as statistically significant.
BMI
Body Mass Index
An anthropometric calculation assessing body fat based on weight and height, calculated as weight in kilograms divided by the square of height in meters (kg/m²).
High BMI (overweight ≥25, obesity ≥30) is a validated risk factor for postmenopausal breast cancer and worse prognostic outcomes due to peripheral estrogen production in adipose tissue.
WHR
Waist-to-Hip Ratio
The ratio of the circumference of the waist to that of the hips, measuring central/abdominal adiposity and visceral fat distribution.
WHR > 0.85 in women indicates visceral adiposity, which is strongly linked with systemic metabolic inflammation, insulin resistance, and increased breast cancer risk in South Asian cohorts.
BP (Systolic / Diastolic)
Blood Pressure
The hydrostatic pressure exerted by circulating blood upon arterial walls, recorded as Systolic (peak pressure during ventricular contraction) over Diastolic (minimum pressure during relaxation).
Tracked in the BCPBD clinical registry. Hypertension is an important comorbidity impacting cardiovascular safety when prescribing anthracyclines and anti-HER2 therapies.
RBS / FBS
Random Blood Sugar / Fasting Blood Sugar
Blood glucose concentration measured either without regard to meal intake (Random Blood Sugar) or after an overnight fast of 8+ hours (Fasting Blood Sugar).
Screening tests for impaired glucose tolerance and diabetes mellitus; chronic hyperglycemia promotes insulin and IGF-1 signaling that may drive oncogenesis.
HbA1c
Glycated Hemoglobin A1c
A biochemical test measuring the percentage of hemoglobin bound to glucose in circulating red blood cells, reflecting average blood glucose control over the preceding 8-12 weeks.
A value ≥6.5% confirms diabetes mellitus. Poor glycemic control during chemotherapy is associated with increased toxicity, infection risk, and adverse survival.
HDL / LDL / TG / TC
High-Density Lipoprotein, Low-Density Lipoprotein, Triglycerides, Total Cholesterol
A complete blood panel measuring circulating cholesterol and lipids. LDL is atherogenic ('bad cholesterol'), HDL is cardio-protective ('good cholesterol'), and TG reflects neutral fat storage.
Atherogenic ratios (TG/HDL, TC/HDL, LDL/HDL) recorded in the BCPBD dataset serve as markers of dyslipidemia, chronic inflammation, and breast cancer metabolic cofactors.
CAD
Coronary Artery Disease
Impaired myocardial blood flow caused by atherosclerotic narrowing or occlusion of coronary arteries.
Recorded in the BCPBD patient questionnaire. An essential cardio-oncology consideration before administering cardiotoxic chemotherapy regimens (such as Doxorubicin).
BSE
Breast Self-Examination
A regular monthly self-inspection and palpation performed by a woman to check her breasts for lumps, skin puckering, changes in shape, or nipple discharge.
A vital, cost-effective early detection awareness practice actively championed in low-resource and rural settings across Bangladesh.
CBE
Clinical Breast Examination
A comprehensive physical breast inspection and manual palpation conducted by a physician, surgeon, or trained healthcare professional.
Key frontline screening modality in low- and middle-income countries where routine nationwide population mammographic screening programs are not widely accessible.
EBRT / RT
External Beam Radiation Therapy
The application of high-energy ionizing photons (X-rays) delivered from a linear accelerator outside the body to destroy microscopic residual cancer cells in the breast or regional lymph nodes.
Standard adjuvant therapy after breast-conserving surgery or in high-risk post-mastectomy cases, reducing loco-regional recurrence by >50%.
WBI
Whole Breast Irradiation
Adjuvant external radiation therapy encompassing the entire mammary gland tissue following breast-conserving surgery (lumpectomy).
Mandatory component of breast conservation therapy (BCS) ensuring local disease recurrence rates match those of mastectomy.
PMRT
Post-Mastectomy Radiation Therapy
Adjuvant radiation targeted to the chest wall and regional draining nodal stations (supraclavicular, axillary, internal mammary) following mastectomy.
Standard recommendation for patients with primary tumors >5 cm (T3/T4) or involvement of 4 or more axillary lymph nodes (N2/N3).
LVI
Lymphovascular Invasion
The microscopic presence of cancer cell clusters inside the lumina of lymphatic channels or small blood vessels outside the main tumor mass.
An adverse pathological prognostic factor that correlates with higher axillary nodal involvement, distant metastasis, and higher recurrence risk.
PNI
Perineural Invasion
The histological observation of neoplastic cells tracking along, surrounding, or invading nerve sheaths in the breast tissue.
Indicates aggressive local invasion and carries higher risk of local regional relapse.
Gy (Gray)
Gray (Unit of Absorbed Radiation Dose)
The International System (SI) unit of absorbed ionizing radiation dose, defined as one joule of radiation energy absorbed per kilogram of tissue.
Standard breast cancer adjuvant radiation courses administer a cumulative dose of 40-50 Gy delivered in divided daily fractions (e.g., 2 Gy per fraction or hypofractionated 2.67 Gy).
TCGA
The Cancer Genome Atlas
A landmark multi-institutional genomics project that comprehensively mapped genomic mutations, copy number variations, RNA sequencing, and clinical outcomes across over 1,000 breast invasive carcinomas (TCGA-BRCA).
Integrated into the BCPBD portal's research tools, allowing researchers to explore survival curves, gene expression, and mutation frequencies.
Luminal A Subtype
Luminal A Molecular Breast Cancer Subtype
The most prevalent molecular breast cancer subtype, defined by positive estrogen receptor (ER+) and progesterone receptor (PR+ ≥20%), negative HER2 (HER2-), and low proliferation index (Ki-67 <14-20%).
Carries the most favorable overall prognosis. Highly responsive to endocrine therapies (Tamoxifen, Letrozole); rarely requires adjuvant cytotoxic chemotherapy in node-negative disease.
Luminal B Subtype
Luminal B Molecular Breast Cancer Subtype
Hormone receptor-positive breast cancer (ER+) that is either HER2-positive OR HER2-negative with high cell proliferation (Ki-67 ≥20%) or lower PR levels.
More aggressive and has a higher recurrence rate than Luminal A. Treatment often entails adjuvant chemotherapy in addition to endocrine therapy, plus anti-HER2 therapy if HER2+.
HER2-Enriched Subtype
HER2-Enriched Molecular Breast Cancer Subtype
A subtype featuring high amplification and overexpression of the ERBB2/HER2 oncogene, usually testing negative for hormone receptors (ER-, PR-).
Characterized by rapid growth and higher historical recurrence rates, now effectively managed with targeted anti-HER2 regimens (Trastuzumab + Pertuzumab + chemotherapy).
Basal-like Subtype
Basal-like Molecular Breast Cancer Subtype
An intrinsic gene expression subtype that substantially overlaps with triple-negative breast cancer (ER-, PR-, HER2-), expressing basal cytokeratins (CK5/6, CK14, CK17) and EGFR.
Associated with earlier age of onset, aggressive histology, visceral metastatic patterns, and frequent TP53 mutations.
Ki-67 Proliferation Index
Antigen Ki-67 Cellular Proliferation Marker
A nuclear protein expressed during all active phases of the cell division cycle (G1, S, G2, M) but entirely absent in quiescent cells (G0).
Quantified as a percentage of positive tumor cell nuclei. A score ≥20% denotes high proliferation, distinguishing high-risk Luminal B tumors from indolent Luminal A tumors.
BRCA1
Breast Cancer Susceptibility Gene 1
A critical tumor suppressor gene located on chromosome 17q21 encoding a protein that repairs double-strand DNA breaks via homologous recombination.
Hereditary germline pathogenic mutations confer up to 70% lifetime risk of breast cancer and 40% risk of ovarian cancer. Often manifests as aggressive, basal-like TNBC; highly sensitive to PARP inhibitors (Olaparib) and platinum salts.
BRCA2
Breast Cancer Susceptibility Gene 2
A tumor suppressor gene on chromosome 13q12.3 that interacts with RAD51 to coordinate high-fidelity homologous recombination repair of DNA breaks.
Pathogenic mutations lead to high lifetime risk of breast and ovarian cancer in women, as well as elevated risk of male breast cancer and pancreatic cancer. Also actionable with PARP inhibitors.
TP53
Tumor Protein P53 ('Guardian of the Genome')
A central tumor suppressor gene on chromosome 17p13 that arrests cell cycle progression to facilitate DNA repair or triggers apoptosis when damage is irreparable.
Mutated in ~30% of breast cancers overall and >80% of basal-like TNBC. Loss-of-function somatic mutations cause genomic instability and aggressive disease.
PIK3CA
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Subunit Alpha
An oncogene encoding the p110α catalytic subunit of PI3K, stimulating the downstream AKT/mTOR cascade to promote cell growth, motility, and survival.
Mutated in 30-40% of ER+/HER2- breast cancers. Hotspot mutations (e.g. H1047R, E545K) are directly actionable with PI3K-alpha inhibitors (Alpelisib) combined with fulvestrant.
GATA3
GATA-Binding Protein 3
A zinc-finger transcription factor vital for normal luminal epithelial cell differentiation in the mammary gland.
One of the most frequently mutated genes in Luminal A and Luminal B breast cancers. High GATA3 expression strongly correlates with ER positivity and favorable prognosis.
CDH1
Cadherin 1 (E-Cadherin)
A transmembrane glycoprotein that mediates calcium-dependent intercellular adhesion, maintaining epithelial tissue architecture.
Biallelic loss of CDH1 through mutation or deletion is the molecular hallmark of Invasive Lobular Carcinoma (ILC), resulting in discohesive cells growing in single-file patterns.
Cancer Stages (0 to IV)
Breast Cancer Clinical & Pathological Stages (0, I, II, III, IV)
The anatomical extent of cancer in the body: Stage 0 (non-invasive / in situ); Stage I (early, small localized tumor ≤2 cm without lymph nodes); Stage II (localized with limited node spread); Stage III (locally advanced / large tumor or multiple involved nodes); Stage IV (distant metastasis).
Dictates clinical management strategy: Stages I-III are treated with curative intent (surgery, radiotherapy, systemic therapy), whereas Stage IV focuses on disease control and prolonging survival.
Nottingham Histologic Score
Nottingham Combined Histologic Grade (Elston-Ellis Modification)
The universal grading system evaluating three microscopic features: Tubule Formation (1-3), Nuclear Pleomorphism (1-3), and Mitotic Count per 10 high-power fields (1-3). Scores sum from 3 to 9.
Grade 1 (score 3-5, well-differentiated, slowest growing); Grade 2 (score 6-7, moderately differentiated); Grade 3 (score 8-9, poorly differentiated, highly proliferative and aggressive).
Ductal Calcification
Microcalcifications in Breast Ducts
Microscopic calcium deposits formed within mammary ducts due to cellular secretions or necrosis of malignant cells, appearing as fine white specks or clusters on mammograms.
A key radiographic sign of Ductal Carcinoma In Situ (DCIS) and early non-palpable invasive ductal cancer, prompting stereotactic biopsy.
Ductal Extension
Ductal Extension of Carcinoma
The continuous or discontinuous spread of malignant cells extending along the lumen and walls of mammary ducts beyond the central tumor mass.
An important parameter when assessing surgical margins in breast-conserving surgery to ensure complete excision and avoid residual disease.
Surgical Resection Margins
Surgical Margin Status (Negative, Close, Positive)
The edge or border of tissue removed during surgery, examined microscopically after applying surgical ink. 'Negative' (no tumor cells at ink); 'Positive' (tumor cells touch inked edge); 'Close' (<1-2 mm distance).
The surgical guideline 'no ink on tumor' is required for invasive cancer to minimize local recurrence risk; positive margins necessitate re-excision.
Gross vs Microscopic Pathology
Macroscopic (Gross) and Microscopic Pathological Examination
Gross pathology involves visual inspection, sizing, palpation, and specimen orientation with the naked eye. Microscopic pathology involves examining thin tissue sections stained with H&E under high magnification.
Gross pathology determines primary tumor dimensions and lymph node count; microscopic pathology determines histologic subtype, Nottingham grade, receptor expression, and vascular invasion.
Mammography
Screening and Diagnostic Mammography
A specialized low-dose X-ray examination of the compressed breast tissue used to detect non-palpable masses, microcalcifications, and architectural distortions.
The most widely proven screening method for early breast cancer detection, reducing mortality by 20-30% in women aged 40-74.
Breast Ultrasound (Sonography)
High-Resolution Breast Ultrasonography
An imaging modality using high-frequency sound waves to visualize breast tissue architecture without ionizing radiation.
Essential adjunctive tool to mammography; especially valuable in women with dense breast tissue and for distinguishing fluid-filled benign cysts from solid suspicious masses.
Breast MRI
Contrast-Enhanced Magnetic Resonance Imaging of the Breast
An advanced imaging technique utilizing strong magnetic fields, radio waves, and intravenous gadolinium contrast to generate high-resolution cross-sectional breast images.
Recommended for high-risk surveillance (e.g. BRCA mutation carriers), assessing disease extent in invasive lobular carcinoma, and evaluating response to neoadjuvant chemotherapy.
Multigene Expression Assays
Genomic Recurrence Assays (Oncotype DX, MammaPrint)
Molecular diagnostic tests measuring mRNA expression levels of panels of 21 to 70 breast cancer-related genes to quantify residual recurrence risk score.
Used in early-stage ER+/HER2- breast cancer to identify patients who can safely omit adjuvant chemotherapy, sparing unnecessary toxicity.
Trastuzumab (Herceptin)
Trastuzumab Recombinant Monoclonal Antibody
A humanized IgG1 monoclonal antibody that binds specifically to subdomain IV of the extracellular domain of the HER2 protein receptor.
Revolutionized HER2+ breast cancer therapy, reducing the risk of recurrence by almost 50% and significantly extending survival when administered with chemotherapy.
Tamoxifen
Tamoxifen Citrate Selective Estrogen Receptor Modulator
An oral selective estrogen receptor modulator (SERM) that binds competitively to estrogen receptors on breast carcinoma cells, blocking estrogen-mediated transcription.
The cornerstone adjuvant endocrine drug for premenopausal and postmenopausal ER+ patients, taken daily for 5 to 10 years to reduce recurrence and mortality.
Aromatase Inhibitors (Letrozole / Anastrozole / Exemestane)
Third-Generation Aromatase Inhibitors
Oral non-steroidal (Letrozole, Anastrozole) and steroidal (Exemestane) agents that inhibit the peripheral aromatase enzyme responsible for synthesizing estrogens in postmenopausal women.
First-line endocrine therapy for postmenopausal ER+ breast cancer, superior to Tamoxifen in disease-free survival.
Doxorubicin (Adriamycin)
Doxorubicin Hydrochloride Anthracycline Chemotherapy
A potent cytotoxic anthracycline antibiotic that intercalates into DNA base pairs and inhibits topoisomerase II, leading to DNA double-strand breaks and cell death.
Foundation of standard chemotherapy regimens (e.g. AC: Adriamycin + Cyclophosphamide) for moderate-to-high risk early and locally advanced breast cancer. Monitored for potential cardiotoxicity.
Paclitaxel / Docetaxel
Taxane Chemotherapy (Paclitaxel and Docetaxel)
Plant alkaloid-derived cytotoxic agents that bind to and stabilize beta-tubulin microtubules, blocking mitotic spindle disassembly and arresting cell division in the G2/M phase.
Routinely sequenced following anthracyclines (e.g., AC-T regimen) in adjuvant and neoadjuvant therapy, significantly improving disease-free and overall survival.
PARP Inhibitors (Olaparib / Talazoparib)
Poly (ADP-Ribose) Polymerase Inhibitors
Targeted oral medications that trap PARP enzymes on single-strand DNA breaks, exploiting 'synthetic lethality' in cancer cells with homologous recombination defects (such as BRCA1/2 mutations).
Approved for adjuvant treatment of high-risk HER2- early breast cancer and metastatic breast cancer harboring germline BRCA1/2 mutations.
Immunotherapy (Pembrolizumab)
Immune Checkpoint Inhibitor (anti-PD-1 / anti-PD-L1)
Monoclonal antibodies that block the programmed cell death-1 (PD-1) pathway on T-cells, reversing immune evasion and allowing cytotoxic T-cells to attack tumor cells.
Combined with chemotherapy in high-risk early triple-negative breast cancer and PD-L1-positive metastatic TNBC, substantially improving pathological complete response (pCR) and overall survival.
Lymphedema
Secondary Upper-Extremity Breast Cancer-Related Lymphedema
Chronic swelling of the arm, breast, or chest wall resulting from the accumulation of protein-rich lymphatic fluid due to surgical disruption or irradiation of axillary lymphatics.
A major survivorship complication whose incidence is drastically reduced by adopting Sentinel Lymph Node Biopsy (SLNB) in place of routine Axillary Lymph Node Dissection (ALND).
Age at Menarche
Early Menarche (Age at First Menstrual Period)
The chronological age at which a female experiences her first menstrual cycle, recorded as a baseline demographic and reproductive variable in the BCPBD dataset.
Early menarche (<12 years old) increases lifetime cumulative exposure of breast epithelium to endogenous ovarian estrogens, modestly increasing breast cancer risk.
Age at Menopause
Late Menopause & Menopausal Status
The permanent cessation of ovarian menses for 12 consecutive months. Pre-, peri-, and post-menopausal status are fundamental clinical stratifiers in BCPBD.
Late natural menopause (>55 years) prolongs estrogen exposure and elevates breast cancer risk. Postmenopausal status dictates the choice of endocrine therapy (Aromatase Inhibitors over Tamoxifen).
Parity & Nulliparity
Obstetric Parity and Number of Full-Term Pregnancies
Parity refers to the total number of full-term pregnancies; nulliparity designates having never delivered a viable child.
Full-term pregnancy at an early age (<25 years) and high multiparity provide long-term protection against ER+ breast cancer by promoting terminal maturation of mammary lobules.
Lactation Duration
Cumulative Lifetime Breastfeeding Duration
The total duration (in months or years) a woman has breastfed her children throughout her reproductive lifetime.
Extended cumulative breastfeeding (>12 months) significantly lowers lifetime breast cancer risk by inducing epithelial differentiation and suppressing ovulatory menstrual cycles.
Serum Creatinine
Serum Creatinine Renal Biomarker
A breakdown product of creatine phosphate from muscle metabolism excreted by the kidneys, recorded in milligrams per deciliter (mg/dL) in the BCPBD biochemical panel.
Essential for evaluating baseline renal filtration (eGFR). Impaired renal clearance necessitates dose adjustments for chemotherapy agents like Cyclophosphamide, Methotrexate, and platinum salts.
Oral Contraceptive & HRT Use
Exogenous Hormone Use (Oral Contraceptive Pills / Hormone Replacement Therapy)
The therapeutic ingestion of synthetic estrogens and progestins for pregnancy prevention (OCP) or relief of postmenopausal vasomotor symptoms (HRT).
Prolonged combined HRT and current OCP use are associated with a slight transient increase in breast cancer risk that normalizes several years after cessation.
Oncoprint Heatmap
Oncoprint Multi-Gene Genomic Matrix
A visual matrix where columns represent individual patient tumor samples and rows represent selected cancer driver genes, displaying somatic mutations, copy number amplifications, and deletions as color-coded tiles.
Used in the BCPBD and TCGA analytical dashboards to illustrate mutational co-occurrence, mutual exclusivity, and recurrent alteration frequencies.
Kaplan-Meier Survival Analysis
Kaplan-Meier Product-Limit Estimator
A non-parametric statistical method estimating the probability of patient survival over time, accounting for censored observations.
Generates survival step curves to compare prognostic differences across molecular subtypes, tumor stages, or gene expression cohorts, accompanied by log-rank test p-values.
Chi-Square Test (χ²)
Pearson's Chi-Square Test of Independence
A statistical hypothesis test assessing whether an observed distribution of categorical variables in a contingency table differs significantly from an expected null distribution.
Used in the BCPBD 2x2 calculator to identify significant associations between patient lifestyle or dietary risk factors and cancer incidence.
Hypoxia Score
Ragnum / Buffa / Winter Tumor Hypoxia Gene Signature
A computational gene expression score calculated from hypoxia-responsive genes, quantifying cellular oxygen deprivation within the tumor microenvironment.
High hypoxia scores indicate aggressive, poorly oxygenated tumors with increased angiogenesis, radioresistance, and elevated metastatic potential.
Log2 Fold Change (Log₂FC)
Binary Logarithm of Differential Gene Expression Ratio
A mathematical transformation representing the ratio of gene expression levels between two biological cohorts (e.g. tumor vs normal tissue) on a base-2 logarithmic scale.
A Log₂FC of +1 denotes a two-fold upregulation in tumor tissue; a Log₂FC of -1 denotes a 50% downregulation. Core metric in differential expression plots.
p-value
Statistical Significance Probability Value
The probability of obtaining test results at least as extreme as the observed results under the assumption that the null hypothesis is true.
A p-value < 0.05 is commonly used to reject the null hypothesis and establish statistical significance in clinical associations and genomic differential expression.
Smoking Status
Cigarette / Tobacco Smoking Status
History and habit of cigarette or bidi smoking, recorded as a categorical behavioral risk variable.
Tobacco carcinogens induce DNA methylation alterations and increase cardiovascular and pulmonary comorbidities in cancer cohorts.
Tobacco Usage
Smokeless and Chewed Tobacco Usage
Smokeless or chewed tobacco consumption (including jarda, gul, sada pata, and khaini) prevalent in South Asian demographics.
Demonstrates high prevalence in Bangladeshi female cohorts; acts as a potent chemical carcinogen causing localized mucosal and systemic toxicity.
Alcohol Consumption
Alcohol Intake Status
History and frequency of alcohol consumption among study participants.
Established modifiable breast cancer risk factor that elevates circulating endogenous estrogens and disrupts hepatic folate metabolism.
Athlete / Intensive Training
Athletic Conditioning and High Physical Activity
Engagement in competitive athletics or sustained high-intensity physical conditioning.
Protective lifestyle phenotype associated with lowered adiposity, reduced circulating insulin-like growth factors (IGF-1), and lower systemic inflammation.
Fish Oil Supplementation
Dietary Fish Oil and Marine Omega-3 Intake
Dietary intake of marine fish oil providing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Exhibits anti-inflammatory, anti-thrombotic, and triglyceride-lowering effects across metabolic and cardiovascular profiles.
ER Status (Estrogen Receptor)
Estrogen Receptor Positive / Negative Status
Immunohistochemical determination of nuclear estrogen receptor expression in breast tumor cells.
Determines responsiveness to targeted hormonal/endocrine therapies (Tamoxifen, Letrozole) and stratifies clinical prognosis.
Breast Cancer Molecular Subtypes (BC Types)
Intrinsic Molecular Breast Cancer Subtypes
Classification of breast carcinomas based on IHC expression of ER, PR, and HER2 into Luminal A, Luminal B, HER2-enriched, and Triple-Negative (TNBC).
Essential for tailoring precision oncology regimens, predicting treatment sensitivity, and estimating distant recurrence risks.
Cancer Cells in Biopsy
Malignant Cell Detection in Diagnostic Biopsy
Microscopic cytological or histological detection of malignant epithelial cells in fine needle aspiration (FNAC) or core needle biopsy specimens.
Definitive diagnostic evidence distinguishing benign breast disease from invasive carcinoma before definitive surgery.
Prescribed Drugs / Regimen
Prescribed Chemotherapeutic and Endocrine Drug Regimens
Systemic pharmacological regimens administered to breast cancer patients, including AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel), Carboplatin, and Letrozole/Tamoxifen.
Characterizes therapeutic patterns and standard-of-care medication implementation across the cohort.
Treatment Start Year
Year of Oncology Treatment Initiation
The specific calendar year in which active medical, surgical, or radiation oncology treatment was initiated.
Enables longitudinal trend assessment, time-to-treatment analysis, and survival interval calculations.
Family History with Diabetes
Familial Predisposition to Type 2 Diabetes
Presence of diagnosed Type 2 Diabetes Mellitus in first-degree (parents, siblings) or second-degree biological relatives.
Reflects inherited metabolic vulnerability, insulin resistance predisposition, and shared environmental determinants.
Family History with Hypertension
Familial Predisposition to Essential Hypertension
Presence of chronic essential hypertension in first-degree biological relatives.
Key indicator of genetic cardiovascular susceptibility and arterial stiffness interacting with metabolic syndrome.
Employment Status (Formal Service)
Formal Salaried Employment vs. Homemaker
Categorization of formal salaried job holder status (government service, teaching, corporate, healthcare, garments) versus non-salaried homemaker / housewife.
Critical socioeconomic determinant reflecting occupation type, daytime physical activity, daily routine, and systemic healthcare accessibility.

